E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X -X X X a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e u r o p e a n u r o l o g y . c o m Evidence acquisition: A systematic literature search was undertaken incorporating Medline, Embase, and the Cochrane Library. Studies were critically appraised for risk of bias (QUIPS). For prognosis, the primary outcome was progression to muscle-invasive or metastatic disease. Secondary outcomes were disease recurrence, and overall and cancer-specific survival. For reproducibility, the primary outcome was interobserver variability between pathologists. Secondary outcome was intraobserver variability (repeatability) by the same pathologist.
1.

Introduction
Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) have tumour recurrence, and about 10-15% progress to muscle-invasive disease [1] . Accurate prediction of tumour recurrence and progression is important to determine appropriate therapy and follow-up. Tumour grade is an important predictor of tumour prognosis [2] . However, histopathological classifications are known to be limited by inter-and intraobserver variability, which may have profound prognostic implications [3] .
Current European Association of Urology (EAU) recommendations for grading of NMIBC indicate that both the 1973 and the 2004/2016 World Health Organization (WHO) classification should be used [4] . The 1973 classification distinguishes three different grades and evaluates microscopic features related to the degree of cellular atypia, necrosis, and mitotic activity. Grade 1 (G1) carcinomas (well-differentiated) are defined as showing only mild degrees of cytological atypia and infrequent mitotic figures. Grade 3 (G3) carcinomas (poorly differentiated) are defined as showing marked nuclear pleomorphism, loss of maturation from the base to the surface, and mitotic activity. Grade 2 (G2) carcinomas (moderately differentiated) comprise all tumours between these extremes [5] . The lack of clarity between the three grades may adversely affect prognostic prediction due to high intra-and interobserver variability. Furthermore, there is a tendency to classify the majority of tumours in the middle group (G2) [6] .
In an attempt to reduce variability and increase reproducibility, a new grading system based on more detailed histological criteria has been promoted since 1998 by the International Society of Urological Pathology (ISUP) and was subsequently adopted by the WHO in 2004. The main aim was to standardise the classification and grading of urothelial neoplasms, creating a uniform terminology for use by pathologists and urologists [7, 8] . Under the 2004 system, some G1 lesions are classified as papillary urothelial neoplasms with low malignant potential (PUNLMPs) and others are classified as low grade (LG); G2 lesions are classified as LG or high-grade (HG) urothelial carcinomas; G3 lesions as HG urothelial carcinomas ( Fig. 1) . Recently, an update of the 2004 WHO grading classification was published without substantial changes, so the 2004 WHO classification is now known as 2016 WHO classification [9] .
By eliminating the heterogeneous moderately differentiated (G2) category of the 1973 system, the 2004/2016 classification was expected to provide a more reproducible stratification of patients with differing prognoses and welldefined recommendations for treatment and follow-up. However, several studies have shown considerable interobserver variability and its anticipated superior prognostic value is still a matter of debate [6, 10] .
This systematic review compares the prognostic performance and reproducibility of the 1973 WHO and 1998 ISUP/ 2004 WHO/2016 WHO grading systems for NMIBC.
Evidence synthesis: Of 3593 articles identified, 20 were included in the prognostic review; three were eligible for the reproducibility review. Increasing tumour grade in both classifications was associated with higher disease progression and recurrence rates. Progression rates in grade 1 patients were similar to those in low-grade patients; progression rates in grade 3 patients were higher than those in high-grade patients. 
2.2.
Types of study designs
Prospective and retrospective studies comparing the two grading systems were included. Only studies published from 1998 onwards were included. There were no language restrictions. A minimum follow-up of 3 mo (recurrence and/ or progression) was required for inclusion in the prognostic review. Reproducibility assessment by two or more pathologists required use of identical specimens and grading systems. For the assessment of the repeatability of a grading system by the same pathologist, each pathologist or group of pathologists had to assess identical specimens using the same grading system at more than one time point.
Types of participants
Study inclusion criteria were as follows: adult patients (>18 yr old) with primary or recurrent Ta/T1 urothelial carcinoma of the bladder who underwent a transurethral resection of bladder tumour (TURBT). All risk groups and adjuvant treatments were included. Exclusion criteria were as follows: patients under 18 yr; muscle-invasive bladder cancer (MIBC); clinical N+ or M+; grading based on radical cystectomy specimen; and bladder biopsies only (as opposed to TURBT). The protocol allowed inclusion of studies with exclusion criteria if affected patients constituted <10% of the study population.
Type of outcome measures
In the prognostic review, the primary outcome was progression to muscle-invasive or metastatic stage. Secondary outcomes were bladder recurrence, and overall and cancer-specific survival. All outcomes were measured at least 3 mo post-TURBT. In the reproducibility review, the primary outcome was interobserver variability (reproducibility) between pathologists. The secondary outcome was intraobserver variability (repeatability) by the same pathologist and reliability (variability due to heterogeneity of patient populations).
Assessment of risk of bias
As recommended by the Cochrane Prognosis Methods Group, the risk of bias (RoB) in the included studies was assessed using the QUIPS tool across six domains: study participation, attrition, prognostic factor measurement, outcome measurement, confounders, and statistical analysis [11] . The EAU NMIBC Guidelines Panel identified intravesical BCG (yes/no), stage (Ta/T1), and concomitant carcinoma in situ (CIS) (yes/no) as three most important prognostic confounders. The Cochrane Collaboration recommends not to combine domains or give overall summary scores [12] . We used Revman 5.3 software to generate graphs showing RoB for each domain, within and across studies.
Data extraction and analysis
In the prognostic review, outcome events along with all unadjusted (univariate) and adjusted (multivariable) measures of association, such as odds ratios and hazard ratios, were extracted, including those in subgroups of interest.
In the reproducibility review, all outcomes of reproducibility, repeatability, and reliability, both overall and in subgroups of interest, were extracted. Assessment of concordance was evaluated using Cohen's kappa statistic (coefficient k). Arbitrary guidelines characterise values of kappa > 0.75 as excellent concordance, 0.40-0.75 as fair to good, and below 0.40 as poor [13] .
3.
Evidence synthesis 3.1.
Quantity of evidence identified
The study selection process is outlined in the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow diagram (Fig. 2) . A total of 3593 abstracts were reviewed for both prognostic performance and reproducibility, of which 34 full texts were retrieved for further screening. Ultimately, 22 eligible studies were identified; however, two studies [14, 15] were excluded as subsequent publications provided updated data [16, 17] . Finally, 20 studies recruiting a total of 4505 patients met the inclusion criteria for prognostic performance [3, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Three of these studies involving 566 patients met the reproducibility inclusion criteria [3, 16, 33] .
Characteristics of the 20 included studies
The baseline characteristics of studies included in the prognostic review are detailed in Figure 3 presents the RoB summary for the 20 included trials [3, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . We found the highest RoB in study attrition (incomplete outcome data), study confounders (validity, reliability, and similarity of measurement), and study participation (representativeness of the study sample) [10] . The risk of reporting bias (selective reporting) was high in less than one-third of studies. The risks of bias in prognostic factor (tumour grade) measurement and outcome measurement (adequacy of outcome measurement) were low. For the three most important prognostic confounders, tumour stage was well described, but presence of CIS and use of adjuvant treatment were incompletely reported (Table 1) . Therefore, it was difficult to factor these last two confounders into the analyses. Some subgroup analyses were performed in Ta and T1 patients (Tables 2 and 3 ).
Comparisons of prognostic outcome measures
For analysis of progression, recurrence, and overall and cancer specific survival, most available information concerned the number of patients with an event during
Fig. 2 -PRISMA diagram (applicable for both prognostic and reproducibility reviews). MIBC = muscle-invasive bladder cancer; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analysis. * = Three of those studies were also eligible for the reproducibility part. CIS = carcinoma in situ; G1 = grade 1; G2 = grade 2; G3 = grade 3; HG = high grade; LG = low grade; PUNLMP = papillary urothelial neoplasm with low malignant potential. a Studies included in the reproducibility part. follow-up and the percentage of patients with an event at a given point in time. There were little time-to-event data, that is, time to recurrence, hazard ratios, p values, and multivariable adjustments. The main analysis is thus based on a comparison of the overall percentage of patients with an event during follow-up. The data from each study was combined to obtain an overall estimate and compared using a Pearson chi-square test. This was not possible for the percentage of patients with an event at a given point in time.
While it was possible to independently compare the outcomes for the categories within each of the two grading classifications, 1973 (G1 vs G2 vs G3) and 2004/2016 (PUNLMP vs LG vs HG), not all the studies provided end point information for each grading classification. In order to minimise the RoB when comparing 1973 with 2004/2016, the most reliable results were obtained when analysing only the studies that assessed both grading classifications. Thus, each of the two grading classifications is assessed on the same set of patients so that there are no differences between the two classifications concerning patient follow-up, characteristics, or treatment. Sensitivity analyses were carried out using all available information for each grading classification.
3.4.1. Prognostic outcomes 3.4.1.1. Progression. Overall, 13 studies provided data on progression. In six studies, progression was defined as any increase in disease stage, including Ta-T1, while in seven studies, it was defined as an increase to stage T2 or greater. In two studies [18, 32] where data for both definitions were available, information on an increase to T2 or greater was used. (Table 2) .
A separate subgroup analysis of HG T1 disease showed a higher progression rate in G3 versus G2: 28% versus 12%. Table 2) .
In LG Ta patients, we found a higher progression rate in G2 patients as compared with G1 patients: 7% versus 1%.
3.4.1.1.2.2. Comparison using all available data. Progression rates were (G1 vs G2 vs G3) 3% versus 9% versus 28%, and (PUNLMP vs LG vs HG) 2% versus 4% versus 19%, respectively.
3.4.1.2. Recurrence. Eight studies provided information on the number of patients with recurrence, but only five used both grading systems (Table 3) . 
Please cite this article in press as: Soukup The pooled recurrence rates were (G1 vs G2 vs G3) 33% versus 42% versus 63% and (PUNLMP vs LG vs HG) 20% versus 38% versus 55%, respectively (Table 3) .
The majority of patients in these five studies had Ta disease; a separate analysis in T1 patients was not possible [16, 20, 26, 30, 33] . A subgroup analysis of T1 HG patients revealed a higher recurrence rate in G3 patients compared with G2 patients (68% vs 50%) [22] . (Table 3 ).
Separate analysis of Ta patients revealed higher recurrence rates in G3 disease (G1 vs G2 vs G3): 39% versus 41% versus 71%, respectively; in Ta patients, PUNLMP patients have lower recurrence rates than LG or HG patients: 28% versus 52% versus 60%, respectively. No comparisons were possible in T1 patients (Table 3) .
3.4.1.3. Death due to bladder cancer. Only one study provided limited information regarding death due to bladder cancer, so no conclusions could be drawn [29] .
3.4.1.4. Death due to any cause. Information on all-cause mortality was available on a limited basis in two studies [18, 28] , and only one study contributed to the analysis [31] . In this study, death rates for patients with the best and worst prognosis seem to be similar in the two grading classifications, but no conclusions can be drawn. Table 4 .
The interobserver agreement for the 1973 classification ranged from 38% to 89% (kappa values from 0.003 to 0.68). Agreement in combined assessment of G1 + G2 versus G3 tumours in two studies [3, 16] Table 5 . Only two studies assessed the repeatability of both grading systems [3, 15] . The intraobserver agreement for the 1973 WHO grading classification ranged from 63% to 95% (kappa values 0.61-0.88). Repeatability for combined assessment of G1 + G2 versus G3 tumours was slightly higher than that for a separate analysis of G1 versus G2 versus G3 tumours (88-95% vs 63-81%, kappa values 0.64-0.88 vs 0.61-0.69). The intraobserver agreement for the 2004/2016 WHO grading classification ranged from 71% to 93% (kappa values 0.56-0.83). In the only study that assessed the difference between combined and separate pathological reviews, repeatability of group PUNLMP + LG versus HG was higher than that of PUNLMP versus LG versus HG (86-90% vs 71-82%, kappa values 0.68-0.80 vs 0.56-0.69) [3] . In this study, two additional pathologists assessed slides twice using the 2004/2016 WHO classification with 72% and 88% agreement for separate review of PUNLMP versus LG versus HG (kappa values 0.55 and 0.81, respectively), and 85% and 97% LG vs HG 87% (81-91%) 0.70 (0.59-0.81) G2 56% G3 65% van Rhijn (2010) [3] G1 vs G2 vs G3 agreement for combined review of PUNLMP + LG versus HG (kappa values 0.70 and 0.91, respectively).
Discussion
Principal findings
This study demonstrates that both classifications identify patients at risk of tumour progression and recurrence; the risk rises significantly with increasing grade. Additionally, we found that the 2004/2016 classification identifies patients with generally better prognosis. Our analysis demonstrates lower progression rates in all three grades of the 2004/2016 classification compared with the 1973 classification. Progression rates in G1 patients were similar to those in LG patients, while the rates in G3 patients were higher than those in HG patients. We found a lower recurrence rate in PUNLMP versus G1 patients, but a higher recurrence rate in G3 compared with HG patients.
Reproducibility assessment was hindered by a paucity of available studies [3, 33] . In both studies, the interobserver reproducibility for G1 versus G2 versus G3 tumours was poor (kappa values 0.003-0.365), while the interobserver reproducibility for PUNLMP versus LG versus HG was poor to fair (kappa values 0.17-0.516). Comparing the reproducibility of G1 + G2 versus G3 and PUNLMP + LG versus HG tumours, kappa values were slightly higher for the 2004/ 2016 classification (0.44-0.58 vs 0.46-0.72). These findings suggest that the interobserver reproducibility of the2004/ 2016 classification may be slightly better than that of the 1973 classification; however, the interobserver kappa values for both systems are disappointingly low.
The repeatability of both 1973 and 2004/2016 classifications was assessed in two studies [3, 16] . In general, the intraobserver repeatability for G1 versus G2 versus G3 for the two pathologists was good (kappa values 0.61-0.69), whereas the repeatability for PUNLMP versus LG versus HG was fair to good (kappa values 0.56-0.83). Moreover, repeatability for G1 + G2 versus G3 and PUNLMP + LG versus HG was good to excellent (kappa values 0.88 and 0.80, respectively). One study [16] suggests that the intraobserver repeatability of the 2004/2016 classification may be better than that of the 1973 classification; however, another demonstrated no difference [3] . To address this, a discussion of the background, rationale, and critique of both grading systems is essential. Tumour grade is routinely used to determine prognosis, treatment, and follow-up of patients with NMIBC. Ideally, a grading system has to be practical, reproducible, and prognostically valid. Although the 1973 classification is well understood by clinicians, it has been criticised for a poorly defined G2 category, seen as a ''default diagnosis''. Pathologists tend to classify a majority of tumours into the middle group when using a three-tier grading system [35] .
The 2004/2016 classification is based on better-defined histological criteria. In theory, this should reduce inter-and intraobserver variability within a two-tiered classification, with the addition of PUNLMP category. However, several studies have shown considerable interobserver variability using the WHO 2004/2016 system [3, 16, 33] .
There are several groups that are problematic for both grading systems: 3.5.2.1. G2 category. A high percentage of NMIBC is classified as G2 disease; previous studies have suggested that this is due to a lack of a clear definition of this category [8, 36] . The proportion of G2 tumours in the 20 studies analysed in this systematic review was 50%; G1 tumours comprised 29% and G3 tumours 21%. This confirms the tendency to classify most patients as G2 in the 1973 classification and corresponds to the incidence of G2 tumours reported in the literature, which varies from 13% to 69% [37, 38] . system was to improve the stratification of patients according to the risk of progression [8] . However, the inclusion of some G2 patients significantly enlarges the high-risk group. The percent of patients with HG tumours was two-fold higher (1887 cases, 42%) than those with G3 tumours (929 cases, 21%; Table 1 ). Treating HG tumours the same as G3 disease could lead to overtreatment of patients PUNLMP is defined as a papillary urothelial tumour that resembles exophytic urothelial papilloma but shows increased cellular proliferation exceeding the thickness of normal urothelium [8] . The introduction of this new category in the 2004/2016 WHO classification aimed to avoid labelling these patients with the term ''cancer'' to decrease psychosocial and economic burdens [37] . The published incidence of PUNLMP ranges from 12% to 39%, with recurrence rates between 25% and 60% and stage progression rates between 2% and 8%, very similar to the LG carcinomas [30, 32, 41, 42] .
Ten studies in this systematic review reported a total of 624 patients with PUNLMP and 1303 with G1 tumours [3, 17, 20, [26] [27] [28] [30] [31] [32] [33] [34] . Tumour recurrence occurred in 75 patients with PUNLMP and 111 G1 tumours (12% vs 9%).
Tumour progression of PUNLMP, defined as any stage increase, was reported in eight studies [3, 17, 20, 26, 27, [31] [32] [33] . Progression was diagnosed in six of 354 PUNLMP patients and 16 of 704 G1 patients (1.7% vs 2.3%). Progression to muscle-invasive disease from PUNLMP is very rare; it was found in one of 93 PUNLMP patients (1.1%) and eight of 250 G1 patients (3.2%).
Our study supports existing data demonstrating that progression of PUNLMP to muscle-invasive tumour is rare. The risk of recurrence and stage increase is comparable in PUNLMP and G1 patients. Moreover, molecular profiles of PUNLMP and G1 categories are similar [34] . Consequently, patients diagnosed with PUNLMP should be followed up in the same manner as patients with noninvasive G1 tumours.
3.5.2.4. T1 category. T1 tumours are rarely classified as LG [43] . As such, the 2004/2016 system does not allow differentiation of T1 tumours in subgroups with distinct prognoses [23] .
Distribution of 2004/2016 WHO grade in the subgroup of T1 patients was reported in three studies included in our systematic review [22, 23, 29] . Of 681 T1 tumours, only 13 were classified as LG (1.9%).
Recurrence and progression are more frequent in G3 than in HG tumours. Dividing HG T1 disease into G2 and G3, a higher recurrence rate (50% vs 68%) was found in one study [22] and a higher progression rate (12% vs 28%) was reported in two studies [22, 29] . On the basis of these findings, the 1973 system may provide more accurate prognostic information in pT1 tumours. One solution may be the creation of new classification for grade, including elements from both 1973 and 2004/2016 systems, as suggested by van Rhijn et al [34] .
Limitations and strengths of the review
Although this systematic review gives the best evidence we have so far, the quality of the evidence obtained was low, based on the absence of well-designed prospective studies with low RoBs. Heterogeneity in study designs, populations, treatment, definition of progression, incomplete reporting of outcome data, and lack of individual patient data limited the analyses that could be done and made meta-analysis inappropriate.
The main analysis in this systematic review is based on the studies for which both 1973 and 2004/2016 classifications were assessed. This approach has minimised bias and is the major strength of this review. Regarding the reproducibility part of the review, one study [16] appeared to present the overall global agreement and global kappa statistics, and not the agreement between pairs of pathologists as was done in the other two studies. Moreover, only two studies with a total of three pathologists assessed the intraobserver variability between the 1973 and 2004/2016 WHO classifications.
Conclusions
The Drafting of the manuscript: Soukup, Č apoun, Cohen, Herná ndez, Sylvester.
